Glynis Reede supports healthcare organizations with research and analysis on a wide range of health policy issues.
Before joining Avalere, Glynis served as an analyst at a boutique healthcare advisory firm where she researched and wrote about Medicaid, biosecurity, artificial intelligence in healthcare, hospitals, hospital payment rules, and the 2024 elections. She also researched and analyzed private equity’s effects on rural hospitals and organizations throughout the United States.
Glynis holds a bachelor’s degree in politics & international affairs, art history and bioethics, humanities, and medicines from Wake Forest University where she graduated Magna Cum Laude.
Authored Content
A second Trump administration and Republican Congress will mark a shift in healthcare policy priorities in 2025 on both legislative and regulatory fronts.
HRSA 2023 340B purchase data demonstrates continued program growth and that sales for the top 10 340B drugs exceeded sales for those drugs in Medicare.
During the debate, VP candidates outlined their views on healthcare topics such as the ACA, drug pricing, manufacturing, reproductive rights, and mental health.
Stakeholders consider implementation of a 340B rebate model to address duplicate discount risk.
Sixty-nine percent of 340B contract pharmacies were associated with a PBM through vertical integration (53%) or contractual arrangement (16%).
With key health policy differences between presidential candidates, the 2024 elections are an inflection point for the future of US healthcare.
In preparation for the 2024 state legislative sessions, stakeholders should consider how states will continue to shape the 340B policy landscape.
Some federal grant recipients use 340B program eligibility to expand their reach and services provided to a wide range of patient populations.
Key 340B stakeholders include the federal government, patients, pharmacies, drug manufacturers, PBMs, plans, and the 340B prime vendor.
Section 340B of the Public Health Service Act requires significant discounts on outpatient drugs for “covered entities"—safety-net providers and programs.